RxDoctor Payments Data

Robert Arieli

Internal Medicine · Los Angeles, CANPI 1245573708

Payments from drug & device makers

$648in general payments, 2019–2025

Across 29 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Recordati_rare_diseases_inc.$122
  • Lilly USA, LLC$100
  • Bayer$95
  • Novo Nordisk$85
  • Abbott$79
  • Boehringer Ingelheim$33
  • plus $133 from 6 others

What the payments were for

  • Food & beverage$648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$648 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$75,974
Medicare patients
204
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$159,530
JardianceEmpagliflozin58$75,799
TrulicityDulaglutide35$50,542
JanuviaSitagliptin Phosphate35$44,259
EliquisApixaban48$42,748
LinzessLinaclotide38$26,353
EntrestoSacubitril/Valsartan13$14,716
Atorvastatin Calcium393$2,714
Gabapentin99$2,419
Losartan Potassium249$2,109
Metformin Hcl214$1,567
Albuterol Sulfate HfaAlbuterol Sulfate55$1,441
Levothyroxine Sodium103$1,380
Tamsulosin Hcl113$1,197
Famotidine69$1,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$85$159,530109 claims
Boehringer IngelheimJardiance$33$75,79958 claims
Lilly USA, LLCTrulicity$100$50,54235 claims
NovartisEntresto$29$14,71613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →